Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) An antibody or functional fragment thereof which binds with (e.g. to) and neutralises human NOGO.

2. (Original) An antibody according to claim 1 which binds to a region of human NOGO-A protein between amino acids 586 to 785.

3. (Original) An antibody according to claim 2 which binds to a region of human NOGO-A between amino acids 586 to 685.

4. (Original) An antibody according to claim 2 which binds to a region of human NOGO-A between amino acids 686 to 785.

5. (Original) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs: SEQ.I.D.NO:1, 2 and 3

Heavy chain CDRs:SEQ.I.D.NO: 4,5 and 6.

6. (Original) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs: SEQ.I.D.NO:7, 8 and 9

Heavy chain CDRs: SEQ.I.D.NO:10,11 AND 12.

7. (Original) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs:SEQ.I.D.NO:13,14 AND 15;

Heavy chain CDRs: SEQ.I.D.NO:16,17 AND 18.

8. (Original) An antibody according to claim 5 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

9. (Original) An antibody according to claim 6 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

10. (Original) An antibody according to claim 7 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

11. (Currently amended) An antibody of ~~any one of claims 1 to 10~~ claim 1 which is a monoclonal antibody.

12. (Currently amended) An antibody of ~~any one of claims 1 to 13~~ claim 1 which is a humanised or chimeric antibody.

13. (Original) An antibody according to claim 8 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ.I.D.NO:37

14. (Original) An antibody according to claim 9 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ.I.D.NO:38.

15. (Original) An antibody according to claim 10 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:39.

16. (Currently amended) An antibody according to claim 8 ~~or 13~~ wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:40.

17. (Currently amended) An antibody according to claim 9 ~~or 14~~ wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:41.

18. (Original) An antibody according to claim 10 ~~or 15~~ wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:42.

19. (Currently amended) A pharmaceutical composition comprising an anti-NOGO antibody or functional fragment thereof according to ~~any preceding~~ claim 1 together with a pharmaceutically acceptable diluent or carrier.

20. (Currently amended) ~~A~~ The method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody, according to ~~any one of claims 1-18~~ claim 1, including altered antibodies or a functional fragment thereof.

21. (Cancelled)

22. (Currently amended) ~~A~~ The method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease/disorder which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody according to ~~any one of claims 1-18~~ claim 1, including altered antibodies or a functional fragment thereof.

23. (Cancelled)

24. (Currently amended) ~~A~~ The method of treating or prophylaxis of stroke or other neurological disease/disorder in a human comprising the step of parenteral administration of a therapeutically effective amount of an anti-NOGO antibody according to ~~any one of claims 1 to 18~~ claim 1 to said human.

25. (Original) The method of claim 24 wherein the anti-NOGO antibody is administered intravenously.

26. (Currently amended) The method of ~~any one of claims 20~~ claim 20 ~~to 24~~ wherein the other neurological disease/disorder is selected from the group consisting of;

traumatic brain injury, spinal cord injury, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.

27. (Currently amended) ~~A~~ The method of promoting axonal sprouting comprising the step of contacting a human axon with an anti-NOGO antibody of ~~claims 1 to 18~~ claim 1.

28. (Original) The method of claim 27 wherein the method is in vitro.

29. (Currently amended) ~~A~~ The method of producing an anti-NOGO antibody of ~~any one of claims 1 to 18~~ claim 1 which specifically binds to and neutralises the activity of human NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) co-transfecting a mammalian host cell with said first and second vectors;

(d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;

(e) recovering the secreted antibody of step (d).

30. (Currently amended) ~~A~~ The method of producing an anti-NOGO antibody that competitively inhibits the binding of the antibody of ~~any one of claims 1 to 18~~ claim 1 which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) co-transfecting a mammalian host cell with said first and second vectors;

(d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;

(e) recovering the secreted antibody of step (d).

31. (Currently amended) ~~A~~ The method of producing an intravenously administrable pharmaceutical composition comprising an anti-NOGO antibody which binds to and neutralises the activity of NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;

(d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;

(e) recovering (and optionally purifying) the secreted antibody of step (d);

(f) incorporating the antibody of step (e) into a intravenously administrable pharmaceutical composition.

32. (Currently amended) ~~A~~ The method of producing an anti-NOGO antibody which binds to human NOGO-A between amino acids 586-785, particularly 586-685 or 686 to 785 and neutralises the activity of said NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;

(d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;

(e) recovering (and optionally purifying) the secreted antibody of step (d);

33. (Currently amended) ~~A~~ The method according to claim 29 ~~to 32~~ wherein the host cell is selected from the group consisting of; NS0 Sp2/o, CHO, COS, a fibroblast cell such as 3T3, particularly CHO.